Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update

Kevin McFarthing; Sue Buff; Gary Rafaloff; Kenneth Pitzer; Brian Fiske; Anaya Navangul; Katelyn Beissert; Aleksandra Pilcicka; Rosie Fuest; Richard K. Wyse; Simon R.W. Stott

doi:10.3233/jpd-240272

journal article Open Access Jul 18, 2024

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update

Kevin McFarthing Sue Buff Gary Rafaloff Kenneth Pitzer Brian Fiske Anaya Navangul Katelyn Beissert Aleksandra Pilcicka Rosie Fuest Richard K. Wyse

Simon R.W. Stott

Journal of Parkinson’s Disease Vol. 14 No. 5 pp. 899-912 · SAGE Publications

View at Publisher Save 10.3233/jpd-240272

Abstract

Background: For the past five years, our annual reports have been tracking the clinical development of new drug-based therapies for the neurodegenerative condition of Parkinson’s disease (PD). These reviews have followed the progress both of “symptomatic treatments” (ST – improves/reduces symptoms of the condition) and “disease-modifying treatments” (DMT – attempts to delay/slow progression by addressing the underlying biology of PD). Efforts have also been made to further categorize these experimental treatments based on their mechanisms of action and class of drug. Methods: A dataset of clinical trials for drug therapies in PD using trial data downloaded from the ClinicalTrials.gov online registry was generated. A breakdown analysis of all the studies that were active as of January 31st, 2024, was conducted. This analysis involved categorizing the trials based on both the mechanism of action (MOA) and the drug target. Results: There were 136 active Phase 1–3 trials evaluating drug therapies for PD registered on ClinicalTrials.gov, as of January 31, 2024. Of these trials, 76 (56%) were classified as ST trials and 60 (44%) were designated DMT. More than half (58%) of the trials were in Phase 2 testing stage, followed by Phase 1 (30%) and Phase 3 (12%). 35 of the trials were registered since our last report, with the remaining 101 trials appearing in at least one earlier report. Conclusions: The drug development pipeline for PD remains in a robust state with a wide variety of approaches being developed and evaluated in Phase 1 and 2. Yet again, however, only a limited number of DMTs are transitioning to Phase 3.

Topics

No keywords indexed for this article. Browse by subject →

References

35

[1]

10.1016/s1474-4422(23)00109-6

[2]

10.1126/scitranslmed.abo1557

[3]

10.1038/s43587-023-00478-y

[4]

10.1212/wnl.0000000000207748

[5]

Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients, https://ir.vaxxinity.com/news-releases/news-release-details/vaxxinity-demonstrates-target-engagement-toxic-alpha-synuclein (2023, accessed 13 June 2024).

[6]

10.3233/jpd-225111

[7]

Parkinsonism

Margaret M. Hoehn, Melvin D. Yahr

Neurology 10.1212/wnl.17.5.427

[8]

A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria

Günter U Höglinger, Charles H Adler, Daniela Berg et al.

The Lancet Neurology 10.1016/s1474-4422(23)00404-0

[9]

A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research

Tanya Simuni, Lana M Chahine, Kathleen Poston et al.

The Lancet Neurology 10.1016/s1474-4422(23)00405-2

[10]

Michael J. Fox Foundation. Path to Prevention (P2P) Platform Trial: A Phase 2A, Randomized, Double Blind, Placebo Controlled Study to Evaluate Investigational Interventions in Early Stage Neuronal Alpha-Synuclein Disease (NSD), https://www.ppmi-info.org/sites/default/files/docs/P2P-013%20stand%20alone%20synopsis%20and%20SOA%201Apr24.pdf (2024).

[11]

10.1016/s1474-4422(23)00283-1

[12]

Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease

Jonggeol Jeffrey Kim, Dan Vitale, Diego Véliz Otani et al.

Nature Genetics 10.1038/s41588-023-01584-8

[13]

10.1016/j.parkreldis.2023.105517

[14]

10.1038/s41531-023-00456-6

[15]

10.1002/mds.29508

[16]

10.1186/s12883-023-03414-0

[17]

Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)

Clodagh Towns, Madeleine Richer, Simona Jasaityte et al.

npj Parkinson's Disease 10.1038/s41531-023-00533-w

[18]

10.1002/cpt.2819

[19]

10.1002/trc2.12465

[20]

10.1007/s40266-022-00939-w

[21]

10.3390/ph16111513

[22]

10.3233/jpd-239901

[23]

10.1016/j.tins.2023.07.009

[24]

10.3233/jpd-202128

[25]

10.3233/jpd-219006

[26]

10.3233/jpd-229002

[27]

10.1038/s41577-022-00684-6

[28]

10.1056/nejmoa2312323

[29]

Biogen Provides Update on Parkinson’s Disease Clinical Development Program, https://investors.biogen.com/newsreleases/news-release-details/statement-biogen-provides-update-parkinsons-disease-clinical (2023, accessed 13 June 2024).

[30]

Cure Parkinson’s. Phase 2 clinical trial of dapansutrile for Parkinson’s confirmed, https://cureparkinsons.org.uk/2024/02/phase-2-clinical-trial-of-dapansutrile-for-parkinsons-confirmed/ (2024, accessed 13 June 2024).

[31]

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease, https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-first-human-dosing-arv-102-investigational (2024, accessed 13 June 2024).

[32]

Australian Parkinson’s Mission, https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375958&isReview=true (accessed 13 June 2024).

[33]

10.3233/jpd-202346

[34]

AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson’s Disease in the European Union Open a printable version of this pageEmail the URL of this page to a friend, https://news.abbvie.com/-01-09-AbbVie-Launches-PRODUODOPA-R-foslevodopa-foscarbidopa-for-People-Living-with-Advanced-Parkinsons-Disease-in-the-European-Union (2024, accessed 13 June 2024).

[35]

10.1093/brain/awad063

Cited By

76

Organic Chemistry in the Creation of Molecules with Practically Useful Properties

Yu. Yu. Belyakova, I. A. Yaremenko · 2026

Russian Journal of General Chemistr...

The α-synuclein proteostasis network and its translational applications in Parkinson’s disease

Christine M. Lim, Michele Vendruscolo · 2026

Proceedings of the National Academy...

Combining light-induced aggregation and biotin proximity labeling implicates endolysosomal proteins in early α-synuclein oligomerization

Maxime Teixeira, Razan Sheta · 2025

iScience

How to advance the pharmacological management of cognitive impairment in Parkinson's disease

Carla Abdelnour, Lucy L Gibson · 2025

Journal of Parkinson’s Disease

Probiotics as Potential Treatments for Neurodegenerative Diseases: a Review of the Evidence from in vivo to Clinical Trial

Jin Hee Kim, Yujin Choi · 2024

Biomolecules & Therapeutics

Metrics

76

Citations

35

References

Details

Published: Jul 18, 2024
Vol/Issue: 14(5)
Pages: 899-912
License: View

Authors

K

Kevin McFarthing

Parkinson’s Research Advocate, Oxford, UK

S

Sue Buff

Parkinson’s Research Advocate, Sunnyvale, CA, USA

G

Gary Rafaloff

Parkinson’s Research Advocate, Westlake, FL, USA

K

Kenneth Pitzer

Parkinson’s Research Advocate, Pacific Grove, CA, USA

B

Brian Fiske

The Michael J Fox Foundation for Parkinson’s Research, New York, USA

A

Anaya Navangul

Cure Parkinson’s, London, UK

K

Katelyn Beissert

Cure Parkinson’s, London, UK

A

Aleksandra Pilcicka

Cure Parkinson’s, London, UK

R

Rosie Fuest

Cure Parkinson’s, London, UK

R

Richard K. Wyse

Cure Parkinson’s, London, UK

S

Simon R.W. Stott

Cure Parkinson’s, London, UK

Cite This Article

Kevin McFarthing, Sue Buff, Gary Rafaloff, et al. (2024). Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update. Journal of Parkinson’s Disease, 14(5), 899-912. https://doi.org/10.3233/jpd-240272

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update

You May Also Like